公开(公告)号：US5693646A

公开(公告)日：1997-12-02

申请号：US464360

申请日：1995-06-05

Applicant: Todd K. Jones ,  Christopher M. Tegley ,  Lin Zhi ,  James P. Edwards ,  Sarah J. West

Inventor： Todd K. Jones ,  Christopher M. Tegley ,  Lin Zhi ,  James P. Edwards ,  Sarah J. West

IPC: C07D215/06 ,  C07D221/18 ,  C07D311/80 ,  C07D401/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D491/04 ,  C07D491/048 ,  C07D491/052 ,  A61K31/44 ,  C07D491/52

CPC classification number: C07D401/04 ,  C07D215/06 ,  C07D221/18 ,  C07D311/80 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D491/04

Abstract: Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

公开(公告)号：US5677336A

公开(公告)日：1997-10-14

申请号：US141492

申请日：1993-10-21

Applicant: Todd K. Jones ,  Lawrence G. Hamann ,  Luc Farmer ,  Michael G. Johnson ,  Mark E. Goldman

Inventor： Todd K. Jones ,  Lawrence G. Hamann ,  Luc Farmer ,  Michael G. Johnson ,  Mark E. Goldman

IPC: A61K31/04 ,  A61K31/05 ,  A61K31/075 ,  A61K31/12 ,  A61K31/22 ,  C07C39/23 ,  C07C43/23 ,  C07C45/67 ,  C07C45/71 ,  C07C47/575 ,  C07C49/753 ,  C07C69/017 ,  C07C205/06 ,  C07C205/18 ,  C07C205/45 ,  A61K31/085

CPC classification number: C07C205/45 ,  A61K31/04 ,  A61K31/05 ,  A61K31/075 ,  A61K31/12 ,  A61K31/22 ,  C07C205/06 ,  C07C205/18 ,  C07C39/23 ,  C07C43/23 ,  C07C45/673 ,  C07C45/71 ,  C07C47/575 ,  C07C49/753 ,  C07C69/017 ,  C07C2101/14 ,  C07C2101/16

Abstract: Non-steroidal compounds which are high affinity, high specificity ligand antagonists for the androgen receptor are disclosed. Also disclosed are methods for employing the disclosed compounds for modulating processes mediated by the androgen receptor and for treating patients requiring androgen receptor antagonist therapy.

Abstract translation: 公开了对雄激素受体具有高亲和性，高特异性配体拮抗剂的非甾体化合物。 还公开了使用所公开的化合物调节由雄激素受体介导的过程和用于治疗需要雄激素受体拮抗剂治疗的患者的方法。

公开(公告)号：US5514821A

公开(公告)日：1996-05-07

申请号：US250368

申请日：1994-05-27

Applicant: Youssef L. Bennani ,  Marcus F. Boehm

Inventor： Youssef L. Bennani ,  Marcus F. Boehm

IPC: C07C45/29 ,  C07C45/67 ,  C07C69/608 ,  C07C403/20 ,  C07D309/32 ,  C07C57/26

CPC classification number: C07C403/20 ,  C07C403/14 ,  C07C45/29 ,  C07C45/67 ,  C07C69/608 ,  C07D309/32 ,  C07B2200/05 ,  C07B2200/09 ,  C07C2101/16

Abstract: Methods for the synthesis of dideuterium and/or ditritium ring-labeled retinoids and intermediates, and their use in the discovery of Retinoid X Receptor ligands are provided. In addition, dideuterium and/or ditritium ring-labeled retinoids and novel intermediates, as well as methods for their use in ligand binding and mass spectral studies are also provided.

Abstract translation: 提供了合成二氘和/或二铑环标记的类视黄醇和中间体的方法及其在发现维甲酸X受体配体中的用途。 此外，还提供了二氘和/或二铑环标记的类视黄醇和新型中间体，以及其用于配体结合和质谱研究的方法。

公开(公告)号：US11566041B2

公开(公告)日：2023-01-31

申请号：US17835828

申请日：2022-06-08

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi

IPC: C07H17/00 ,  A61K31/706 ,  A61P31/12

Abstract: Provided herein are nucleotide prodrug compounds, their preparation and their uses, such as treating diseases or conditions of a viral infection.

公开(公告)号：US20220204448A1

公开(公告)日：2022-06-30

申请号：US17604729

申请日：2020-04-16

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi ,  Henri Sasmor

IPC: C07D207/08

Abstract: Disclosed herein are methods of crystallizing the compound of Formula (I), as well as crystalline forms thereof. Crystalline forms of Formula (I) disclosed include crystalline Form C, crystalline Form E, and Crystalline form B.

公开(公告)号：US20210121422A1

公开(公告)日：2021-04-29

申请号：US16969521

申请日：2019-02-13

Applicant: LIGAND PHARMACEUTICALS INCORPORATED ,  METAVANT SCIENCES GMBH

Inventor： Lin Zhi ,  Ian Henderson ,  Joseph Kaloko ,  Martin Osterhout

IPC: A61K31/185 ,  C07C309/24 ,  A61K31/155 ,  A61K31/427 ,  A61K31/4439 ,  A61K38/28 ,  A61K38/31 ,  A61K31/7032 ,  A61K31/702 ,  A61K31/64 ,  A61K31/366 ,  A61K31/455 ,  A61K45/06 ,  C07C315/04 ,  C07C201/12 ,  C07C209/36 ,  C07C67/343 ,  C07C67/00 ,  C07C231/02 ,  C07C231/12 ,  C07C315/06

Abstract: Provided herein are solid state forms of compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, ameliorating, delaying the time to onset or reducing the risk for the development or progression of at least one condition, disease, or disorder for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance, hyperglycemia, ketoacidosis, or ketosis.

公开(公告)号：US20210040102A1

公开(公告)日：2021-02-11

申请号：US17071273

申请日：2020-10-15

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi

IPC: C07D487/04

Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using imidazole-fused heterocycle amines. Some of the disclosed embodiments include imizazo-fused heterocycle compounds useful to treat leukemia and other hematopoietic disorders.

公开(公告)号：US20140155379A1

公开(公告)日：2014-06-05

申请号：US14137318

申请日：2013-12-20

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Koc-Kan Ho ,  David Diller ,  Jeffrey J. Letourneau ,  Brian F. McGuinness ,  Andrew G. Cole ,  David Rosen ,  Cornelis A. van Oeveren ,  Jason C. Pickens ,  Lin Zhi ,  Yixing Shen ,  Bijan Pedram

IPC: C07D417/12 ,  C07D513/04 ,  C07D471/04 ,  C07D417/14

CPC classification number: C07D513/04 ,  A61K31/407 ,  A61K31/4168 ,  A61K31/4353 ,  A61P29/00 ,  A61P37/00 ,  C07D235/02 ,  C07D269/02 ,  C07D277/42 ,  C07D277/60 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04

Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.

Abstract translation: 公开了化学和医学领域中的化合物和方法。 一些所公开的实施方案包括使用杂环胺的化合物，组合物和方法。 一些所公开的实施方案包括可用于治疗炎症性疾病的杂环胺。

公开(公告)号：US07919248B2

公开(公告)日：2011-04-05

申请号：US12109780

申请日：2008-04-25

Applicant: Yuhong Zhou ,  Jamila Louahed ,  Nicholas C. Nicolaides ,  Michael McLane ,  Roy C. Levitt

Inventor： Yuhong Zhou ,  Jamila Louahed ,  Nicholas C. Nicolaides ,  Michael McLane ,  Roy C. Levitt

IPC: C12Q1/68 ,  C12Q1/66 ,  C12Q1/25 ,  G01N33/60 ,  C07H21/02

CPC classification number: C07K16/244 ,  A61K2039/505

Abstract: The present invention is drawn to methods for modulating IL-13 expression and/or activity in a mammal comprising administering an effective amount of an agent which modulates the expression and/or activity of IL-9.

Abstract translation: 本发明涉及用于调节哺乳动物IL-13表达和/或活性的方法，其包括施用有效量的调节IL-9的表达和/或活性的药剂。

公开(公告)号：US07816372B2

公开(公告)日：2010-10-19

申请号：US10566569

申请日：2004-08-23

Applicant: Lin Zhi ,  Esther Martinborough ,  Yixing Shen ,  Thomas Lot Stevens Lau ,  Min Wu ,  Yun Oliver Long

Inventor： Lin Zhi ,  Esther Martinborough ,  Yixing Shen ,  Thomas Lot Stevens Lau ,  Min Wu ,  Yun Oliver Long

IPC: C07D215/38 ,  A61K31/02

CPC classification number: C07D401/04

Abstract: The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by AR. Also provided are methods of making such compounds and pharmaceutical compositions.

Abstract translation: 本发明涉及用于调节由AR介导的过程的化合物，药物组合物和方法。 还提供了制备这些化合物和药物组合物的方法。